Wolfe projects a positive outlook for Pharma & Large-Cap Biotech stocks despite potential policy changes as part of Make America Healthy Again movement. Read more here.

Wolfe Research initiated coverage of Veracyte (VCYT) with an Outperform rating and $50 price target Published first on TheFly – the ...

Investors often prefer to invest in shares held by company insiders, as management is typically more aligned with the company’s success and shareholder interests. Currently, insiders own just 0.09% of ...

Wolfe Research has recently raised Warner Bros Discovery Inc (WBD) stock to Peer Perform rating, as announced on November 11, 2024, according to Finviz. Earlier, on August 13, 2024, Bernstein had ...

Tobin Marcus, Wolfe Research policy and politics head, joins CNBC's 'Squawk Box' to discuss what Trump's pick for HHS ...

Fintel reports that on November 15, 2024, Wolfe Research initiated coverage of Biogen (NasdaqGS:BIIB) with a Peer Perform ...

Wolfe Research analyst Alexandria Hammond initiated coverage of Moderna (MRNA) with an Underperform rating and $40 price target Moderna may ...

GWO stock has recently made headlines with its steady growth. As of November 8, 2024, GWO stock sits at around $46.84, up ...

If you want consistent income, look to consistent dividend payers. These three stocks are some of the best in the business ...

State medical boards aren't doing enough to discipline potentially dangerous doctors, according to a report from Public ...

Voters really don't like inflation. In fact, whenever there's a sustained jump in the cost of living, the party in power ...

Bank stocks largely boosted the Dow, as investors hope the sector could see weaker regulation in a second Trump ...